Mahrous AbouSalim

Dr. Mahrous AbouSalim

orcid

Research Focus & Metrics

Academic Career Length

16Years (2011-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 March 2016 in Saudi Pharmaceutical Journal
Verified
Journal Article
Open access
SMSamia G. Abdel Moty
Samia G. Abdel Moty
Mostafa A. HussienMostafa A. Hussien
Mostafa A. Hussien
SASalah A. Abdel Aziz
Salah A. Abdel Aziz
MAMahrous AbouSalim
Mahrous AbouSalim
In continuation to our previous work, thiazolopyrimidines 2a-x were synthesized through intramolecular cyclization of 2-phenacylthio-dihydropyrimidine hydrobromides 1a-x using polyphosphoric acid. On the other hand, thiazolo[3,2-a]pyrimidine-3-one 3 was coupled with aryldiazonium salts or condensed with isatin to afford compounds 4a-c or 5, respectively. Chemical structure of the target compounds was substantiated by IR, FT-IR, (1)H-, (13)C and DEPT-(13)C NMR, MS as well as microanalyses. Moreover, the lipophilicity of the target compounds is expressed as Clog P. The antimicrobial screening of the test compounds 2a-x, 4a-c and 5 revealed moderate activity in comparison to reference drugs. Compounds 2a-c, 2e, 2o and 2v showed a gradual increase in their anti-inflammatory activity reaching its maximum at 5 h compared to indomethacin. Furthermore, the analgesic activity of compounds 2a-c, 2e, 2o and 2v revealed a maximum activity after 5 h of injection compared to aspirin and the LD50 of compounds 2e and 2v was determined.

1 June 2017 in Bioorganic & Medicinal Chemistry
Verified
Journal Article
Closed access
YEYaseen Elshaier
Yaseen Elshaier
MSMohamed A. Shaaban
Mohamed A. Shaaban
MHMohammed K. Abd El Hamid
Mohammed K. Abd El Hamid
MAMostafa H. Abdelrahman
Mostafa H. Abdelrahman
MAMahrous AbouSalim
Mahrous AbouSalim
FHFathi Halaweish
Fathi Halaweish

1 April 2019 in Bioorganic Chemistry
Verified
Journal Article
Closed access
MAMahrous AbouSalim
Mahrous AbouSalim
MSMohamed A. Shaaban
Mohamed A. Shaaban
MHMohammed K. Abd El Hameid
Mohammed K. Abd El Hameid
YEYaseen Elshaier
Yaseen Elshaier
FHFathi Halaweish
Fathi Halaweish

18 February 2022 in Pharmaceuticals
Verified
Journal Article
Open access
PDF file
MMMater H. Mahnashi
Mater H. Mahnashi
Fardous F. El-SendunyFardous F. El-Senduny
Fardous F. El-Senduny
MAMohammed Abdulrahman Alshahrani
Mohammed Abdulrahman Alshahrani
MAMahrous AbouSalim
Mahrous AbouSalim
Over the past few decades, the development of broad-spectrum anticancer agents with anti-angiogenic activity has witnessed considerable progress. In this study, a new series of pyrazolo[3,4-d]pyrimidines based on a phenylfuroxan scaffold were designed, synthesized, and evaluated, in terms of their anticancer activities. NCI-60 cell one-dose screening revealed that compounds 12a–c and 14a had the best MGI%, among the tested compounds. The target fluorinated compound 12b, as the most active one, showed better anticancer activity compared to the reference drug sorafenib, with IC50 values of 11.5, 11.6, and 13 µM against the HepG-2, A2780CP, and MDA-MB-231 cell lines, respectively. Furthermore, compound 12b (IC50 = 0.092 µM) had VEGFR-2-inhibitory activity comparable to that of the standard inhibitor sorafenib (IC50 = 0.049 µM). Furthermore, the ability of compound 12b in modulating MAPK signaling pathways was investigated. It was found to decrease the level of total ERK and its phosphorylated form, as well as leading to the down-regulation of metalloproteinase MMP-9 and the over-expression of p21 and p27, thus leading to subG1 cell-cycle arrest and, thus, the induction of apoptosis. Additionally, compound 12b decreased the rate of wound healing in the absence of serum, in comparison to DMSO-treated cells, providing a significant impact on metastasis inhibition. The quantitative RT-PCR results for E-cadherin and N-cadherin showed lower expression of the neuronal N-cadherin and increased expression of epithelial E-cadherin, indicating the ability of 12b to suppress metastasis. Furthermore, 12b-treated HepG2 cells expressed a low level of anti-apoptotic BCL-2 and over-expressed proapoptotic Bax genes, respectively. Using the DAF-FM DA fluorescence probe, compound 12b produced NO intracellularly as efficiently as the reference drug JS-K. In silico molecular docking studies showed a structural similarity through an overlay of 12b with sorafenib. Interestingly, the drug-likeness properties of compound 12b met the expectations of Pfizer’s rule for the design of new drug candidates. Therefore, this study presents a novel anticancer lead compound that is worthy of further investigation and activity improvement.

9 February 2021 in Molecules
Verified
Journal Article
Open access
PDF file
AHAbdel Haleem Mostafa Hussein
Abdel Haleem Mostafa Hussein
AKAhmed A. Khames
Ahmed A. Khames
AEAbu-Bakr A. El-Adasy
Abu-Bakr A. El-Adasy
AAAhmed A. Atalla
Ahmed A. Atalla
MAMohamed Abdel-Rady
Mohamed Abdel-Rady
Assem BarakatAssem Barakat
Assem Barakat
The elaboration of new small molecules that target phosphodiesterase enzymes (PDEs), especially those of type 5 (PDE5), is an interesting and emerging topic nowadays. A new series of heterocycle-based aminothiazoles were designed and synthesized from the key intermediate, 3-oxo-N-(thiazol-2-yl)butanamide (a PDE5 inhibitor that retains its amidic function), as an essential pharmacophoric moiety. The PDE5 inhibitors prevent the degradation of cyclic guanosine monophosphate, thereby causing severe hypotension as a marked side effect. Hence, an in vivo testing of the target compounds was conducted to verify its relation with arterial blood pressure. Utilizing sildenafil as the reference drug, Compounds 5, 10a, and 11b achieved 100% inhibitions of PDE5 without significantly lowering the mean arterial blood pressures (115.95 ± 2.91, 110.3 ± 2.84, and 78.3 ± 2.57, respectively). The molecular docking study revealed that the tested compounds exhibited docking poses that were similar to that of sildenafil (exploiting the amide functionality that interacted with GLN:817:A). The molecular shape and electrostatic similarity revealed a comparable physically achievable electrostatic potential with the reference drug, sildenafil. Therefore, these concomitant results revealed that the tested compounds exerted sildenafil-like inhibitory effects (although without its known drawbacks) on blood circulation, thus suggesting that the tested compounds might represent a cornerstone of beneficial drug candidates for the safe treatment for erectile dysfunction.

20 April 2023 in Journal of Enzyme Inhibition and Medicinal Chemistry
Verified
Journal Article
Open access
MMMater Mahnashi
Mater Mahnashi
MAMohammed Merae Alshahrani
Mohammed Merae Alshahrani
AAAmer Al Ali
Amer Al Ali
AAAbdulaziz Asiri
Abdulaziz Asiri
MAMahrous AbouSalim
Mahrous AbouSalim
A novel series of multifunctional pyrazolo[3,4-d]pyrimidine-based glutamate analogs (6a–l and 7a,b) have been designed and synthesized as antifolate anticancer agents. Among the tested compounds, 6i exhibited the most potent anti-proliferative activity towards NSCLC, CNS, Ovarian, Prostate, Colon, Melanoma, Breast, and Renal cancers with good to weak cytostatic activity and non-lethal actions. 6i demonstrated higher selectivity for cancer than normal cells. 6i could significantly increase the accumulation of S-phase cells during the cell cycle distribution of cancer cells with high potency in the induction of apoptosis. The results unveiled that 6i probably acts through dual inhibition of DHFR and TS enzymes (IC50 = 2.41 and 8.88 µM, correspondingly). Docking studies of 6i displayed that N1-p-bromophenyl and C3-Methyl groups participate in substantial hydrophobic interactions. The drug-likeness features inferred that 6i met the acceptance criteria of Pfizer. Taking together, 6i could be a promising prototype for further optimization as an effective anticancer drug.